GlassScriptPhysician profile
Arihant Jain
NPI 1396910469
$1,623.25
in general payments reported to CMS, 2019-2025
24 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $105 · 2021: $268 · 2022: $206 · 2023: $417 · 2024: $143 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $783.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $388.50 | 2020-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $165.53 | 2019-2025 | Airsupra |
| Abbvie INC. | $161.72 | 2022-2023 | |
| Lilly USA, LLC | $113.27 | 2019-2024 | Mounjaro |
| Viatris Specialty LLC | $88.53 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $79.30 | 2021-2023 | Xarelto |
| Sunovion Pharmaceuticals INC. | $75.57 | 2019 | |
| Merck Sharp & Dohme LLC | $73.63 | 2019 | |
| Baudax Bio INC. | $62.63 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $49.41 | 2023 | Rebyota |
| Sanofi Pasteur INC. | $47.59 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $39.48 | 2019 | |
| Verona Pharma, INC. | $35.14 | 2025 | Ohtuvayre |
| Daiichi Sankyo INC. | $34.79 | 2023 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $29.85 | 2023 | Abilify Maintena, Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $27.00 | 2025 | The Cologuard Plus Collection Kit |
| Circassia INC. | $25.31 | 2019 | |
| Novo Nordisk INC | $25.05 | 2020-2021 | |
| Glaxosmithkline, LLC. | $21.95 | 2023 | Bexsero, Arexvy, Shingrix |
| Optos, INC. | $21.04 | 2021 | |
| Paratek Pharmaceuticals, INC. | $20.39 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $17.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.42 | 2021 | |
| Endogastric Solutions, INC | $7.15 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arihant Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.